Vinay Prasad’s FDA Shake-Up Controversial Tenure & Sudden Exit Explained https://newsplusglobe.medium.com/ Dr. Vinay Prasad, an outspoken critic of FDA policy, was appointed in May 2025 to lead the agency’s vaccine and gene therapy division (CBER). Known for challenging COVID-19 booster policies and cancer drug approvals, his views rattled biotech markets—and by late July, he’d exited amid controversy over gene therapy decisions. This video walks through his tenure, key controversies, and what his departure means for the FDA’s regulatory direction.
